Shares of CryoLife, Inc. (NYSE:CRY) have received a consensus recommendation of “Hold” from the five analysts that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $22.33.
CRY has been the topic of a number of research reports. Northland Securities reissued a “buy” rating and issued a $23.50 target price on shares of CryoLife in a research note on Friday, April 28th. BidaskClub lowered shares of CryoLife from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Finally, Zacks Investment Research lowered shares of CryoLife from a “buy” rating to a “sell” rating in a research note on Wednesday, August 2nd.
In other news, VP Amy Horton sold 9,577 shares of CryoLife stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $20.00, for a total transaction of $191,540.00. Following the sale, the vice president now owns 112,282 shares of the company’s stock, valued at approximately $2,245,640. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 6.00% of the stock is currently owned by insiders.
CryoLife (NYSE CRY) traded up 1.09% during midday trading on Monday, hitting $18.55. The company had a trading volume of 27,832 shares. The company has a 50 day moving average price of $19.33 and a 200 day moving average price of $17.96. CryoLife has a 1-year low of $14.03 and a 1-year high of $20.30. The firm has a market capitalization of $620.42 million, a P/E ratio of 56.21 and a beta of 0.97.
CryoLife (NYSE:CRY) last released its earnings results on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.02. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The business had revenue of $47.80 million for the quarter, compared to analyst estimates of $47.02 million. During the same period last year, the company posted $0.13 EPS. The business’s revenue was up 1.5% on a year-over-year basis. Equities research analysts forecast that CryoLife will post $0.43 earnings per share for the current fiscal year.
CryoLife Company Profile
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
What are top analysts saying about CryoLife Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CryoLife Inc. and related companies.